Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2

Conditions

Gastrointestinal Stromal Tumors 2Colorectal Neoplasms 2Biliary Tract Neoplasms 2Advanced or Metastatic Solid Tumors 2Thymoma 1Solid Tumor 1Sarcoma 1Piebaldism 1Osteosarcoma 1Nasopharyngeal Carcinoma 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumor 1Advanced Renal Cell Carcinoma (aRCC) 1Advanced Refractory Solid Tumors 1

Interventions

Imatinib Mesylate 12Sunitinib 10ripretinib 5regorafenib 4Blood Specimen Collection 3envafolimab 2Specimen Handling 2Paclitaxel 2Magnetic Resonance Spectroscopy 2IDRX-42 2Biopsy 2trastuzumab deruxtecan 1spartalizumab 1ribociclib 1pemigatinib 1palbociclib 1olverembatinib 1nilotinib 1guadecitabine 1binimetinib 1avelumab 1avapritinib 1atezolizumab 1apatinib 1Temozolomide 1TAS-116 1Surgical Instruments 1Sorafenib 1Rogaratinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × envafolimab × 1 year × Clear all
NCT07559864 2026-04-30

Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment

Peking University Cancer Hospital & Institute

Phase 2 Recruiting
100 enrolled
GastrointestinalSarcoma

Piebaldism, Gastrointestinal Stromal Tumors

NCT06772233 2025-07-31

A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment

Peking University

Phase 2 Not yet recruiting
100 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡